Polychemotherapy with Curcumin and Doxorubicin via Biological Nanoplatforms: Enhancing Antitumor Activity DOI Creative Commons
Milad Ashrafizadeh, Ali Zarrabi,

Farid Hashemi

et al.

Pharmaceutics, Journal Year: 2020, Volume and Issue: 12(11), P. 1084 - 1084

Published: Nov. 11, 2020

Doxorubicin (DOX) is a well-known chemotherapeutic agent extensively applied in the field of cancer therapy. However, similar to other agents such as cisplatin, paclitaxel, docetaxel, etoposide and oxaliplatin, cells are able obtain chemoresistance that limits DOX efficacy. In respect dose-dependent side effect DOX, enhancing its dosage not recommended for effective chemotherapy. Therefore, different strategies have been considered reversing resistance diminishing effects. Phytochemical potential candidates this case due their great pharmacological activities. Curcumin antitumor phytochemical isolated from Curcuma longa with capacity suppressing metastasis proliferation affecting molecular pathways. Experiments demonstrated curcumin inhibiting by downregulating oncogene pathways MMP-2, TGF-β, EMT, PI3K/Akt, NF-κB AP-1. Furthermore, coadministration potentiates apoptosis induction cells. light this, nanoplatforms employed codelivery DOX. This results promoting bioavailability internalization aforementioned active compounds and, consequently, activity. Noteworthy, has reducing adverse effects on normal tissues via inflammation, oxidative stress apoptosis. The current review highlights anticancer mechanism, nanovehicles.

Language: Английский

lncRNA-microRNA axis in cancer drug resistance: particular focus on signaling pathways DOI
Raed Obaid Saleh, Mushtak T.S. Al-Ouqaili,

Eyhab Ali

et al.

Medical Oncology, Journal Year: 2024, Volume and Issue: 41(2)

Published: Jan. 9, 2024

Language: Английский

Citations

20
Curcumin in cancer therapy: A novel adjunct for combination chemotherapy with paclitaxel and alleviation of its adverse effects DOI
Milad Ashrafizadeh, Ali Zarrabi,

Farid Hashemi

et al.

Life Sciences, Journal Year: 2020, Volume and Issue: 256, P. 117984 - 117984

Published: June 25, 2020

Language: Английский

Citations

136
The implication of long non-coding RNAs in the diagnosis, pathogenesis and drug resistance of pancreatic ductal adenocarcinoma and their possible therapeutic potential DOI

Gouri Pandya,

Anuradha Kirtonia, Gautam Sethi

et al.

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2020, Volume and Issue: 1874(2), P. 188423 - 188423

Published: Aug. 30, 2020

Language: Английский

Citations

128
Brusatol suppresses STAT3-driven metastasis by downregulating epithelial-mesenchymal transition in hepatocellular carcinoma DOI Creative Commons
Jong Hyun Lee, Chakrabhavi Dhananjaya Mohan,

Amudha Deivasigamani

et al.

Journal of Advanced Research, Journal Year: 2020, Volume and Issue: 26, P. 83 - 94

Published: July 13, 2020

Epithelial-mesenchymal transition (EMT) is a process of transdifferentiation where epithelial cells attain mesenchymal phenotype to gain invasive properties and thus, can contribute metastasis tumor cells.The antimetastatic antitumor efficacy brusatol (BT) was investigated in hepatocellular carcinoma (HCC) model.We evaluated the action BT on EMT using various biological assays HCC cell lines its effect tumorigenesis an orthotopic mouse found that treatment restored expression Occludin, E-cadherin (epithelial markers) while suppressing levels different markers tissues. Moreover, we observed decline transcription factors (Snail, Twist). Since these two be regulated by STAT3 signaling, deciphered influence modulation this pathway. suppressed phosphorylation STAT3Y705 depletion siRNA resulted restoration markers. Importantly, (1mg/kg) reduced burden model with concurrent lung metastasis.Overall, our results demonstrate interferes induced altering EMT-related proteins model.

Language: Английский

Citations

123
Polychemotherapy with Curcumin and Doxorubicin via Biological Nanoplatforms: Enhancing Antitumor Activity DOI Creative Commons
Milad Ashrafizadeh, Ali Zarrabi,

Farid Hashemi

et al.

Pharmaceutics, Journal Year: 2020, Volume and Issue: 12(11), P. 1084 - 1084

Published: Nov. 11, 2020

Doxorubicin (DOX) is a well-known chemotherapeutic agent extensively applied in the field of cancer therapy. However, similar to other agents such as cisplatin, paclitaxel, docetaxel, etoposide and oxaliplatin, cells are able obtain chemoresistance that limits DOX efficacy. In respect dose-dependent side effect DOX, enhancing its dosage not recommended for effective chemotherapy. Therefore, different strategies have been considered reversing resistance diminishing effects. Phytochemical potential candidates this case due their great pharmacological activities. Curcumin antitumor phytochemical isolated from Curcuma longa with capacity suppressing metastasis proliferation affecting molecular pathways. Experiments demonstrated curcumin inhibiting by downregulating oncogene pathways MMP-2, TGF-β, EMT, PI3K/Akt, NF-κB AP-1. Furthermore, coadministration potentiates apoptosis induction cells. light this, nanoplatforms employed codelivery DOX. This results promoting bioavailability internalization aforementioned active compounds and, consequently, activity. Noteworthy, has reducing adverse effects on normal tissues via inflammation, oxidative stress apoptosis. The current review highlights anticancer mechanism, nanovehicles.

Language: Английский

Citations

106